Forensic Analysis · Healthcare / Pharmaceuticals / Biotech · as of Jun 27, 2026
BRIGHT MINDS BIOSCIENCES INC. (DRUG)
A forensic read on BRIGHT MINDS BIOSCIENCES INC. built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.
F · Poor — capital at risk
Forensic grade
Clean
Earnings quality
-20.6%
ROE
$630M
Market cap
BRIGHT MINDS BIOSCIENCES INC. earns a F (Poor — capital at risk) forensic quality grade. No severe earnings-quality or capital-allocation flags appear in its latest filings.
Key fundamentals
Return on Equity-50.6%
Go deeper — free with an account
The forensic grade and screens above are free — no account needed. An account adds the full interactive deep-dive on BRIGHT MINDS BIOSCIENCES INC.:
🔒The written investment read — what the numbers mean, in plain English
🔒Ask anything about DRUG's filings — AI Q&A across the 10-K, 10-Qs & 8-Ks
🔒Interactive valuation — reverse-DCF sliders, Monte Carlo & scenario stress
🔒Calibrated 12-month price forecast, with the math shown
🔒Peer comparison + filing-change monitoring & alerts
No credit card · informational only, not investment advice · see the track record
← Browse all forensic stock analyses
Data from SEC EDGAR public filings · metrics as of Jun 27, 2026. Forensic signals flag probability, not certainty.